查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2136137

模擬軟體市場－2026年至2032年全球市場預測

Biosimulation Software Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物模擬軟體市場將成長至 76.6 億美元，複合年成長率為 9.43%。

主要市場統計數據
基準年 2025 40.7億美元
預計年份：2026年 44.1億美元
預測年份 2032 76.6億美元
複合年成長率 (%) 9.43%

模擬軟體：執行摘要

模擬軟體運用計算模型應對生物學、藥理學和臨床挑戰，支持藥物發現、藥物動力學和動態分析、毒理學、臨床試驗設計和轉化研究等活動。其價值在於能夠將實驗證據與基於機制、統計和系統學的模型結合，從而提高可重複性和決策支援能力。其成功應用取決於模型的可靠性、資料品質、互通性、法規核准、使用者專業知識以及其在製藥、生物技術、學術和公共部門等不同環境中的工作流程適用性。

工作流程整合和模型可靠性正在改變我們實施解決方案的方式。

目前情況正從孤立的建模工作轉向協調的工作流程，將實驗數據、真實世界數據、臨床開發和上市後監測連結起來。雲端技術的應用、標準化的資料結構、應用程式介面 (API) 和協作工作空間促進了跨部門的模型重複使用，但檢驗、文件、網路安全和管治仍然至關重要。各組織也越來越重視可解釋性和可複現性，因為要讓模擬輸出能夠作為重大決策的依據，就必須能夠追溯到假設、資料集、參數選擇和不確定性分析。

人工智慧不會取代機械模擬，而是會擴展其功能。

人工智慧可以加速參數估計、虛擬篩檢、代理模型建構、異常檢測以及從科學文獻和非結構化記錄中提取有用資訊。其最大的貢獻往往是互補的。機器學習技術有助於模式識別和降低計算負荷，而機制模型則提供生物學結構、可解釋性和基於場景的推論。因此，有效實施需要精心選擇訓練資料、前瞻性檢驗、偏差管理、模型監控、人工審核，以及明確區分探索性輸出和適用於監管決策的證據。

區域趨勢反映了監管水準、基礎設施和研究集中度。

在北美，成熟的製藥和生物技術生態系統、先進的研究基礎設施以及與監管機構的積極合作，為從藥物發現到開發的模擬技術廣泛應用提供了支持。在歐洲，強大的學術合作和完善的管理體制，高度重視資料保護、互通性和可重複性。亞太地區受益於不斷擴展的生物醫學研究能力、數位基礎設施和生產能力，但各組織需要應對不同的法規環境和專業知識獲取方面的差異。在拉丁美洲，生物模擬能力正透過研究機構、臨床網路和夥伴關係關係不斷發展，其應用受到資金籌措和技術能力的影響。在中東，對健康研究、數位轉型和創新平台的投資，為基於類比的規劃創造了機會。在非洲，公共衛生、臨床開發和能力建設方面存在著迫切的需求，而進展取決於數據的可用性、計算資源的獲取、本地專業知識以及永續的機構間夥伴關係。

經濟與安全集團塑造合作與標準。

歐盟優先考慮監管協調、隱私保護和跨境研究基礎設施，而七國集團則為協調先進技術、衛生安全和負責任的創新提供了一個平台。金磚國家成員國在科學、人口和製造業方面存在顯著差異，但合作必須考慮到不同的監管框架、資料管治要求和技術成熟度。鑑於東協各國的能力各不相同，它為區域研究協調和數位健康實踐共用提供了機會。海灣合作理事會正在加強醫療衛生系統和研究基礎設施的數位化，以支持精準醫療和臨床規劃的應用。北約成員國有潛力在嚴格的安全、隱私和兩用管治下，將生物模擬應用於生物醫學準備、醫療物流和韌性建設。

每個國家的優先事項都因其研發能力和法規環境。

美國和加拿大在計算生物學、臨床研究和監管科學領域擁有強大的實力。英國、法國、德國、義大利和西班牙將成熟的生命科學研究與歐洲的數據和監管要求結合，但在轉化研究、生產製造和融入醫療保健系統等領域，各國的優先事項有所不同。中國、日本和韓國正在大力投資數位科學、生物醫學研究和尖端技術，其應用受到國家標準和數據政策的影響。印度正在擴展其生物技術、製藥和分析能力，從而催生了對擴充性培訓和可互通工作流程的需求。澳洲透過其卓越的研究和臨床網路支持生物模擬。巴西和墨西哥正透過其製藥、學術和醫療保健生態系統建立自身能力。俄羅斯在科學和製藥領域保持著強大的實力，但合作、數據取得和技術採購可能會受到監管和地緣政治環境的影響。

我們將建構一個管理管治、可互通、以證據為基礎的模擬能力。

產業領導者應首先著眼於與可衡量決策相關的高價值用例，並在擴大部署規模之前建立檢驗標準。他們還應維護透明的模型開發記錄、版本控制、不確定性分析和獨立審查流程，使資料架構符合互通性標準，並將模擬專家與藥理學、臨床、監管、資料科學和資訊安全團隊整合起來。人工智慧驅動的功能應透過使用基準資料集、人工監督、偏差測試和部署後監測的受控初步試驗來實施。如果模擬旨在支援正式申報和臨床決策，組織還應投資於人才培養，根據風險評估雲端和本地部署架構，並儘早與監管機構和研究合作夥伴進行溝通。

調查方法：基於證據的模擬軟體發展趨勢綜合分析

本執行摘要對藥物發現、臨床前、臨床、轉化和健康研究應用中的模擬軟體進行了結構化的定性評估。分析考慮了技術能力、工作流程整合、數據和模型管治、人工智慧、監管預期、基礎設施、技能以及區域和組織環境。區域、群體和國家的具體觀察結果以背景分析而非量化排名的形式呈現。結論是基於研究能力、數位基礎設施、監管成熟度、互通性和組織準備度之間的橫斷面關係。有意排除了需要市場規模估算、佔有率、預測或公司特定資訊揭露的內容。

可靠的整合決定了生物模擬的長期價值。

模擬軟體正逐漸成為生命科學整個工作流程中證據產生和決策支援的核心環節。其影響力更取決於可靠的模型、穩健的數據、透明的管治以及與實驗和臨床環境的整合，而非單純的計算能力。能夠將基於機制的洞見與管理良好的人工智慧相結合、建構跨學科能力並證明其可重複性的機構，將更有利於將模擬結果轉化為科學合理且具有實際應用價值的成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：模擬軟體市場：依產品分類

  • 服務
    • 諮詢
    • 客製化開發
    • 支援與維護
  • 軟體
    • 開放原始碼
    • 專有軟體

第8章：生物模擬軟體市場：依分銷模式分類

  • 基於雲端的
    • 混合雲端
    • 私有雲端
    • 公共雲端
  • 現場

第9章：模擬軟體市場：依應用領域分類

  • 生物資訊學
    • 序列分析
    • 結構生物資訊學
  • 臨床試驗模擬
    • 劑量選擇
    • 測試設計
  • 分子建模與模擬
    • 對接
    • 分子動力學
  • 藥物動力學/動態模型
    • 隔間模型
    • 採用非房室模型進行分析
  • 系統生物學
    • 網路分析
    • 路徑建模
  • 虛擬篩檢
    • 基於配體的
    • 結構基礎

第10章：模擬軟體市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第11章：模擬軟體市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：模擬軟體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：模擬軟體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Advanced Chemistry Development
  • Ansys, Inc.
  • Certara, LP
  • Dassault Systemes SE
  • Genedata AG
  • Lixoft SAS
  • Medidata Solutions, Inc.
  • PerkinElmer, Inc.
  • Physiomics Plc
  • Simulations Plus, Inc.
  • Thermo Fisher Scientific Inc.
  • Wolfram Research, LLC

第16章 主要專家

Product Code: MRR-961F26FD6656

The Biosimulation Software Market is projected to grow by USD 7.66 billion at a CAGR of 9.43% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.07 billion
Estimated Year [2026] USD 4.41 billion
Forecast Year [2032] USD 7.66 billion
CAGR (%) 9.43%

Biosimulation Software: Executive Summary

Biosimulation software applies computational models to biological, pharmacological, and clinical questions, supporting activities such as drug discovery, pharmacokinetic and pharmacodynamic analysis, toxicology, clinical trial design, and translational research. Its value is tied to the ability to integrate experimental evidence with mechanistic, statistical, and systems-based models while improving reproducibility and decision support. Adoption depends on model credibility, data quality, interoperability, regulatory acceptance, user expertise, and the ability to fit workflows across pharmaceutical, biotechnology, academic, and public-sector settings.

Workflow Integration and Model Credibility Are Reshaping Adoption

The landscape is shifting from isolated modeling exercises toward connected workflows that link laboratory data, real-world evidence, clinical development, and post-approval monitoring. Cloud deployment, standardized data structures, application programming interfaces, and collaborative workspaces are making it easier to reuse models across functions, although validation, documentation, cybersecurity, and governance remain essential. Organizations are also placing greater emphasis on explainability and reproducibility, because simulation outputs must be traceable to assumptions, datasets, parameter choices, and uncertainty analyses before they can inform high-consequence decisions.

Artificial Intelligence Extends, Rather Than Replaces, Mechanistic Simulation

Artificial intelligence can accelerate parameter estimation, virtual screening, surrogate modeling, anomaly detection, and the extraction of usable information from scientific literature and unstructured records. Its strongest contribution is often complementary: machine-learning methods can identify patterns or reduce computational burden, while mechanistic models provide biological structure, interpretability, and scenario-based reasoning. Effective deployment therefore requires curated training data, prospective validation, bias controls, model monitoring, human review, and clear separation between exploratory outputs and evidence suitable for regulated decisions.

Regional Dynamics Reflect Regulation, Infrastructure, and Research Concentration

In North America, mature pharmaceutical and biotechnology ecosystems, advanced research infrastructure, and active regulatory engagement support broad use across discovery and development. Europe combines strong academic collaboration and regulatory sophistication with a pronounced focus on data protection, interoperability, and reproducibility. Asia-Pacific benefits from expanding biomedical research capacity, digital infrastructure, and manufacturing capabilities, while organizations must manage diverse regulatory environments and uneven access to specialized skills. Latin America is developing biosimulation capabilities through research institutions, clinical networks, and partnerships, with adoption influenced by funding and technical capacity. The Middle East is investing in health research, digital transformation, and innovation platforms, creating opportunities for simulation-enabled planning. Africa has important needs in population health, clinical development, and capacity building; progress depends on data availability, computing access, local expertise, and sustainable institutional partnerships.

Economic and Security Blocs Shape Collaboration and Standards

The European Union emphasizes harmonized regulation, privacy safeguards, and cross-border research infrastructure, while the G7 provides a setting for coordination on advanced technology, health security, and responsible innovation. BRICS members bring substantial scientific, demographic, and manufacturing diversity, but collaboration must account for differing regulatory systems, data governance requirements, and technical maturity. ASEAN offers opportunities for regional research coordination and shared digital-health practices amid varied national capabilities. The GCC is strengthening health-system digitization and research infrastructure, supporting applications in precision medicine and clinical planning. NATO countries may apply biosimulation to biomedical preparedness, medical logistics, and resilience, subject to strict security, privacy, and dual-use governance.

Country Priorities Differ by Research Capacity and Regulatory Context

The United States and Canada benefit from strong computational biology, clinical research, and regulatory-science capabilities. The United Kingdom, France, Germany, Italy, and Spain combine established life-science research with European data and regulatory requirements, while national priorities differ across translational research, manufacturing, and health-system integration. China, Japan, and South Korea have substantial investments in digital science, biomedical research, and advanced technology, with adoption shaped by domestic standards and data policies. India is expanding its biotechnology, pharmaceutical, and analytics capabilities, creating demand for scalable training and interoperable workflows. Australia supports biosimulation through research excellence and clinical networks. Brazil and Mexico are developing capacity through pharmaceutical, academic, and healthcare ecosystems. Russia maintains scientific and pharmaceutical capabilities, though collaboration, data access, and technology procurement can be affected by regulatory and geopolitical conditions.

Build Governed, Interoperable, and Evidence-Ready Simulation Capabilities

Industry leaders should begin with high-value use cases tied to measurable decisions, then establish validation criteria before scaling deployment. They should maintain transparent model-development records, version control, uncertainty analyses, and independent review processes; align data architectures with interoperability standards; and integrate simulation specialists with pharmacology, clinical, regulatory, data-science, and information-security teams. AI-enabled functions should be introduced through controlled pilots with benchmark datasets, human oversight, bias testing, and monitoring after deployment. Organizations should also invest in workforce development, evaluate cloud and on-premises architectures according to risk, and engage regulators and research partners early when simulations are intended to support formal submissions or clinical decisions.

Methodology: Evidence-Based Synthesis of Biosimulation Software Dynamics

This executive summary uses a structured qualitative assessment of biosimulation software across discovery, preclinical, clinical, translational, and health-research applications. The analysis considers technology capabilities, workflow integration, data and model governance, artificial intelligence, regulatory expectations, infrastructure, skills, and regional or institutional conditions. Regional, group, and country observations are framed as contextual insights rather than quantified rankings. Conclusions are based on cross-cutting relationships among research capacity, digital infrastructure, regulatory maturity, interoperability, and organizational readiness; claims requiring market estimates, shares, forecasts, or company-specific disclosure are intentionally excluded.

Trustworthy Integration Will Determine Long-Term Biosimulation Value

Biosimulation software is becoming a core layer for evidence generation and decision support across the life-sciences workflow. Its impact will depend less on standalone computational power than on credible models, reliable data, transparent governance, and integration with experimental and clinical practice. Organizations that combine mechanistic insight with appropriately governed artificial intelligence, build interdisciplinary capability, and demonstrate reproducibility will be better positioned to translate simulation into scientifically defensible and operationally useful outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biosimulation Software Market, by Product

  • 7.1. Introduction
  • 7.2. Services
    • 7.2.1. Consulting
    • 7.2.2. Custom Development
    • 7.2.3. Support & Maintenance
  • 7.3. Software
    • 7.3.1. Open Source
    • 7.3.2. Proprietary Software

8. Biosimulation Software Market, by Delivery Mode

  • 8.1. Introduction
  • 8.2. Cloud Based
    • 8.2.1. Hybrid Cloud
    • 8.2.2. Private Cloud
    • 8.2.3. Public Cloud
  • 8.3. On Premise

9. Biosimulation Software Market, by Application

  • 9.1. Introduction
  • 9.2. Bioinformatics
    • 9.2.1. Sequence Analysis
    • 9.2.2. Structural Bioinformatics
  • 9.3. Clinical Trial Simulation
    • 9.3.1. Dose Selection
    • 9.3.2. Trial Design
  • 9.4. Molecular Modeling & Simulation
    • 9.4.1. Docking
    • 9.4.2. Molecular Dynamics
  • 9.5. Pharmacokinetics/Pharmacodynamics Modeling
    • 9.5.1. Compartmental Modeling
    • 9.5.2. Non Compartmental Analysis
  • 9.6. Systems Biology
    • 9.6.1. Network Analysis
    • 9.6.2. Pathway Modeling
  • 9.7. Virtual Screening
    • 9.7.1. Ligand Based
    • 9.7.2. Structure Based

10. Biosimulation Software Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Contract Research Organizations
  • 10.4. Hospitals & Clinics
  • 10.5. Pharmaceutical & Biotechnology Companies

11. Biosimulation Software Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. Biosimulation Software Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. Biosimulation Software Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Advanced Chemistry Development
  • 15.2. Ansys, Inc.
  • 15.3. Certara, L.P.
  • 15.4. Dassault Systemes SE
  • 15.5. Genedata AG
  • 15.6. Lixoft SAS
  • 15.7. Medidata Solutions, Inc.
  • 15.8. PerkinElmer, Inc.
  • 15.9. Physiomics Plc
  • 15.10. Simulations Plus, Inc.
  • 15.11. Thermo Fisher Scientific Inc.
  • 15.12. Wolfram Research, LLC

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Biosimulation Software Market, Years Considered for the Study
  • FIGURE 2. Global Biosimulation Software Market, Research Design
  • FIGURE 3. Global Biosimulation Software Market, Research Framework
  • FIGURE 4. Global Biosimulation Software Market, Data Triangulation
  • FIGURE 5. Global Biosimulation Software Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Biosimulation Software Market Size, by Product, 2025 vs 2032 (%)
  • FIGURE 7. Global Biosimulation Software Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Biosimulation Software Market Size, by Delivery Mode, 2025 vs 2032 (%)
  • FIGURE 9. Global Biosimulation Software Market Size, by Delivery Mode, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Biosimulation Software Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 11. Global Biosimulation Software Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Biosimulation Software Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global Biosimulation Software Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Biosimulation Software Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Biosimulation Software Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Biosimulation Software Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Biosimulation Software Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Biosimulation Software Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Biosimulation Software Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Biosimulation Software Market Segmentation & Coverage
  • TABLE 2. Global Biosimulation Software Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 4. Global Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Consulting Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Consulting Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Consulting Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Custom Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Custom Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Custom Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Support & Maintenance Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Support & Maintenance Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Support & Maintenance Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Software Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Open Source Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Open Source Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Open Source Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Proprietary Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Proprietary Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Proprietary Software Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 26. Global Cloud Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Cloud Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Cloud Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Hybrid Cloud Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Hybrid Cloud Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Hybrid Cloud Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Private Cloud Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Private Cloud Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Private Cloud Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Public Cloud Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Public Cloud Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Public Cloud Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global On Premise Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global On Premise Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global On Premise Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 42. Global Bioinformatics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Bioinformatics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Bioinformatics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Sequence Analysis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Sequence Analysis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Sequence Analysis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Structural Bioinformatics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Structural Bioinformatics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Structural Bioinformatics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Clinical Trial Simulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Clinical Trial Simulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Clinical Trial Simulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Dose Selection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Dose Selection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Dose Selection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Trial Design Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Trial Design Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Trial Design Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Molecular Modeling & Simulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Molecular Modeling & Simulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Molecular Modeling & Simulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Docking Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Docking Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Docking Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Molecular Dynamics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Molecular Dynamics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Molecular Dynamics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Pharmacokinetics/Pharmacodynamics Modeling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Pharmacokinetics/Pharmacodynamics Modeling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Pharmacokinetics/Pharmacodynamics Modeling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Compartmental Modeling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Compartmental Modeling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Compartmental Modeling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Non Compartmental Analysis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Non Compartmental Analysis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Non Compartmental Analysis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Systems Biology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Systems Biology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Systems Biology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Network Analysis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Network Analysis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Network Analysis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Pathway Modeling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Pathway Modeling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Pathway Modeling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Virtual Screening Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Global Virtual Screening Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. Global Virtual Screening Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 90. Global Ligand Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Global Ligand Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. Global Ligand Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 93. Global Structure Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Global Structure Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 95. Global Structure Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 96. Global Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 97. Global Academic & Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 98. Global Academic & Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 99. Global Academic & Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 100. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 102. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 103. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 104. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 105. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 106. Global Pharmaceutical & Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 107. Global Pharmaceutical & Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 108. Global Pharmaceutical & Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 109. Global Biosimulation Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 110. Asia-Pacific Biosimulation Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Asia-Pacific Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 112. Asia-Pacific Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 113. Asia-Pacific Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 114. Asia-Pacific Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 115. Asia-Pacific Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 116. Asia-Pacific Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 117. Asia-Pacific Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 118. Asia-Pacific Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 119. Asia-Pacific Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 120. Asia-Pacific Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 121. Asia-Pacific Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 122. Asia-Pacific Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 123. Asia-Pacific Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 124. North America Biosimulation Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 125. North America Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 126. North America Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 127. North America Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 128. North America Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 129. North America Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 130. North America Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 131. North America Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 132. North America Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 133. North America Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 134. North America Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 135. North America Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 136. North America Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 137. North America Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 138. Latin America Biosimulation Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 139. Latin America Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 140. Latin America Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 141. Latin America Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 142. Latin America Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 143. Latin America Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 144. Latin America Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 145. Latin America Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 146. Latin America Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 147. Latin America Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 148. Latin America Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 149. Latin America Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 150. Latin America Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 151. Latin America Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 152. Europe Biosimulation Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 153. Europe Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 154. Europe Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 155. Europe Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 156. Europe Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 157. Europe Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 158. Europe Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 159. Europe Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 160. Europe Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 161. Europe Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 162. Europe Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 163. Europe Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 164. Europe Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 165. Europe Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 166. Middle East Biosimulation Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 167. Middle East Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 168. Middle East Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 169. Middle East Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 170. Middle East Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 171. Middle East Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 172. Middle East Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 173. Middle East Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 174. Middle East Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 175. Middle East Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 176. Middle East Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 177. Middle East Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 178. Middle East Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 179. Middle East Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 180. Africa Biosimulation Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 181. Africa Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 182. Africa Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 183. Africa Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 184. Africa Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 185. Africa Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 186. Africa Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 187. Africa Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 188. Africa Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 189. Africa Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 190. Africa Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 191. Africa Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 192. Africa Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 193. Africa Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 194. Global Biosimulation Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 195. ASEAN Biosimulation Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 196. ASEAN Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 197. ASEAN Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 198. ASEAN Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 199. ASEAN Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 200. ASEAN Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 201. ASEAN Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 202. ASEAN Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 203. ASEAN Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 204. ASEAN Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 205. ASEAN Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 206. ASEAN Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 207. ASEAN Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 208. ASEAN Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 209. GCC Biosimulation Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 210. GCC Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 211. GCC Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 212. GCC Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 213. GCC Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 214. GCC Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 215. GCC Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 216. GCC Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 217. GCC Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 218. GCC Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 219. GCC Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 220. GCC Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 221. GCC Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 222. GCC Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 223. European Union Biosimulation Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 224. European Union Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 225. European Union Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 226. European Union Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 227. European Union Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 228. European Union Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 229. European Union Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 230. European Union Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 231. European Union Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 232. European Union Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 233. European Union Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 234. European Union Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 235. European Union Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 236. European Union Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 237. BRICS Biosimulation Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 238. BRICS Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 239. BRICS Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 240. BRICS Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 241. BRICS Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 242. BRICS Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 243. BRICS Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 244. BRICS Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 245. BRICS Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 246. BRICS Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 247. BRICS Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 248. BRICS Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 249. BRICS Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 250. BRICS Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 251. G7 Biosimulation Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 252. G7 Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 253. G7 Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 254. G7 Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 255. G7 Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 256. G7 Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 257. G7 Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 258. G7 Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 259. G7 Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 260. G7 Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 261. G7 Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 262. G7 Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 263. G7 Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 264. G7 Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 265. NATO Biosimulation Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 266. NATO Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 267. NATO Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 268. NATO Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 269. NATO Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 270. NATO Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 271. NATO Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 272. NATO Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 273. NATO Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 274. NATO Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 275. NATO Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 276. NATO Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 277. NATO Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 278. NATO Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 279. Global Biosimulation Software Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 280. United States Biosimulation Software Market Size, 2017-2032 (USD Million)
  • TABLE 281. United States Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 282. United States Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 283. United States Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 284. United States Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 285. United States Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 286. United States Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 287. United States Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 288. United States Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 289. United States Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 290. United States Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 291. United States Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 292. United States Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 293. United States Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 294. Canada Biosimulation Software Market Size, 2017-2032 (USD Million)
  • TABLE 295. Canada Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 296. Canada Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 297. Canada Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 298. Canada Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 299. Canada Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 300. Canada Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 301. Canada Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 302. Canada Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 303. Canada Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 304. Canada Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 305. Canada Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 306. Canada Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 307. Canada Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 308. Mexico Biosimulation Software Market Size, 2017-2032 (USD Million)
  • TABLE 309. Mexico Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 310. Mexico Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 311. Mexico Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 312. Mexico Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 313. Mexico Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 314. Mexico Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 315. Mexico Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 316. Mexico Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 317. Mexico Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 318. Mexico Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 319. Mexico Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 320. Mexico Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 321. Mexico Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 322. Brazil Biosimulation Software Market Size, 2017-2032 (USD Million)
  • TABLE 323. Brazil Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 324. Brazil Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 325. Brazil Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 326. Brazil Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 327. Brazil Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 328. Brazil Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 329. Brazil Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 330. Brazil Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 331. Brazil Biosimulation Software Market Size, by Molecular Modeling & Simulation, 2017-2032 (USD Million)
  • TABLE 332. Brazil Biosimulation Software Market Size, by Pharmacokinetics/Pharmacodynamics Modeling, 2017-2032 (USD Million)
  • TABLE 333. Brazil Biosimulation Software Market Size, by Systems Biology, 2017-2032 (USD Million)
  • TABLE 334. Brazil Biosimulation Software Market Size, by Virtual Screening, 2017-2032 (USD Million)
  • TABLE 335. Brazil Biosimulation Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 336. United Kingdom Biosimulation Software Market Size, 2017-2032 (USD Million)
  • TABLE 337. United Kingdom Biosimulation Software Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 338. United Kingdom Biosimulation Software Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 339. United Kingdom Biosimulation Software Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 340. United Kingdom Biosimulation Software Market Size, by Delivery Mode, 2017-2032 (USD Million)
  • TABLE 341. United Kingdom Biosimulation Software Market Size, by Cloud Based, 2017-2032 (USD Million)
  • TABLE 342. United Kingdom Biosimulation Software Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 343. United Kingdom Biosimulation Software Market Size, by Bioinformatics, 2017-2032 (USD Million)
  • TABLE 344. United Kingdom Biosimulation Software Market Size, by Clinical Trial Simulation, 2017-2032 (USD Million)
  • TABLE 345. United Kingdom Biosimulation Software Market Size, by Molecular Modelin